Physician profile
Kevin Yoon
NPI 1972092674
$1,759.36
in general payments reported to CMS, 2019-2025
27 companies · $583 in 2025
The $583 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $47.30 · 2023: $583 · 2024: $546 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,529.14 |
| Education | $182.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $215.69 | 2022-2025 | Reblozyl, Pomalyst, Opdivo |
| Astrazeneca Pharmaceuticals LP | $166.53 | 2023-2025 | Enhertu, Tagrisso, Calquence |
| Astellas Pharma US INC | $152.60 | 2023-2025 | Xospata |
| Genzyme Corporation | $113.62 | 2023-2024 | |
| Eisai INC. | $91.62 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $84.90 | 2023-2025 | Keytruda, Lynparza |
| Kite Pharma, INC. | $81.73 | 2025 | Yescarta |
| Genentech USA, INC. | $77.63 | 2023-2025 | Tecentriq, Columvi |
| Seagen INC. | $75.69 | 2022-2023 | Adcetris, Tukysa |
| Regeneron Healthcare Solutions, INC. | $73.72 | 2023-2024 | Libtayo |
| Lilly USA, LLC | $65.11 | 2025 | Verzenio, Jaypirca, Retevmo |
| Adc Therapeutics America, INC. | $62.40 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $58.63 | 2023-2024 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $50.10 | 2024 | |
| Incyte Corporation | $49.20 | 2023-2024 | Jakafi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $46.07 | 2023 | |
| Mirati Therapeutics, INC. | $38.62 | 2023 | Krazati |
| Pfizer INC. | $38.57 | 2024 | |
| Karyopharm Therapeutics INC. | $34.15 | 2024 | Xpovio |
| Immunogen, INC. | $29.21 | 2023 | Elahere |
| Atricure, INC. | $28.73 | 2023 | |
| Agios Pharmaceuticals, INC. | $23.45 | 2025 | Pyrukynd |
| Abbvie INC. | $22.72 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $22.55 | 2025 | Opdualag |
| Blueprint Medicines Corporation | $19.45 | 2024 | Ayvakit |
| Array Biopharma INC | $18.36 | 2025 | Mektovi, Xalkori, Braftovi |
| Kyowa Kirin, INC. | $18.31 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Yoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.